Merck Assumes Full Control of MK-8690 Anti-CD30 Ligand Antibody for Inflammatory Bowel Disease
Key Insights
Merck (search) has agreed to pay $150 million to Dr. Falk Pharma (search) to terminate their co-development partnership for MK-8690 (search), securing global rights to the investigational anti-CD30 ligand (search) monoclonal antibody.
The drug candidate, originally developed by Prometheus Biosciences (search) which Merck (search) acquired for $10.8 billion in 2023, is currently being evaluated in early-stage clinical trials for inflammatory bowel diseases.
Dr. Falk remains eligible for development milestone payments and royalties on sales in certain territories, while Merck (search) will assume full responsibility for the development program going forward.
Merck (search) & Co. has reached an agreement with Dr. Falk Pharma (search) GmbH to terminate their existing co-development partnership for MK-8690 (search), an investigational anti-CD30 ligand (search) monoclonal antibody targeting inflammatory bowel diseases. The pharmaceutical giant will pay $150 million upfront to secure global rights to the drug candidate, which was originally part of Merck's $10.8 billion acquisition of Prometheus Biosciences (search) in 2023.
Strategic Consolidation of Development Rights
Under the terms of the agreement announced Tuesday, Merck (search) will assume full responsibility for MK-8690 (search)'s development program, ending the collaboration that Prometheus had established with the German pharmaceutical company in 2020. The original contract had granted Dr. Falk co-development and co-commercialization rights in certain territories for the investigational therapy.
MK-8690 (search), formerly known as PRA-052, represents a novel approach to treating inflammatory bowel diseases through its mechanism as an anti-CD30 ligand (search) monoclonal antibody. The drug candidate is currently being evaluated in an early-stage clinical trial under Merck (search)'s oversight.
Financial Terms and Impact
The transaction structure provides Dr. Falk with immediate compensation while maintaining potential future revenue streams. Beyond the $150 million upfront payment, Dr. Falk remains eligible to receive payments associated with development milestones as well as royalties on sales in certain territories.
Merck (search) will record the transaction as a pre-tax charge to research and development expenses of $150 million in its fourth quarter results, impacting both GAAP and non-GAAP earnings by approximately $0.05 per share. The Rahway, New Jersey-based company indicated this charge reflects the strategic value of consolidating full control over the development program.
Prometheus Acquisition Integration
The move represents continued integration of assets from Merck (search)'s substantial acquisition of Prometheus Biosciences (search), completed in 2023 for $10.8 billion. Prometheus had originally entered into the collaboration with Dr. Falk in 2020, before becoming part of Merck's portfolio of inflammatory disease treatments.
By assuming full control of MK-8690 (search)'s development, Merck (search) gains the ability to make independent strategic decisions regarding clinical trial design, regulatory pathways, and potential commercialization strategies without requiring coordination with a development partner. This consolidation aligns with the company's broader strategy of maintaining direct oversight of promising pipeline candidates in key therapeutic areas.